biopsyneedleInternational Classification of DiseasesinfectionssepsisObjectives The aim of this study was to assess the incidence of infection after transrectal prostate biopsy (TRbx). Secondary objectives were to describe infection characteristics, antibiotic resistance patterns, ICD-10 coding, and costs. ...
cancer (OR: 1.28, p < 0.001) and specifically for significant prostate cancer (OR: 1.46, p < 0.001) in uni-variate analyses. However, multi-variate analyses using age, PSA, prostate volume, DRE and transrectal ultrasonography outcome, and previous biopsy (yes/no) showed that PSAV was not ...
The prostate biopsy rate was defined as the number of prostate biopsy procedures (defined by Current Procedural Terminology, International Classification of Diseases, Ninth Revision [ICD-9], and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] ...
Enrichment of prostate cancer stem cells from primary prostate cancer cultures of biopsy samples. Int J Clin Exp Pathol. 2014;7(1):184–93. PubMed Google Scholar Bertokova A, Svecova N, Kozics K, Gabelova A, Vikartovska A, Jane E, Hires M, Bertok T, Tkac J. Exosomes from ...
related care as follows: costs for PSA screening; prostate biopsies performed within 180 days after a PSA test; and hospitalizations due to biopsy complications, defined as those that occurred within 30 days of prostate biopsies and have ICD-10 primary diagnosis codes consistent with ...
In the intervention arm, men with a raised PSA (X3.0 ng ml À 1) were invited for diagnostic tests including a transrectal ultrasound (TRUS)-guided biopsy. All men subsequently diagnosed with clinically localised prostate cancer (T1-T2, NX, M0) were asked to consider randomisation within ...
Active surveillance was defined as no definitive treatment within the first year of prostate cancer diagnosis and at least 1 additional biopsy after the first diagnostic biopsy. Low-risk prostate cancer was defined as a Gleason score of 6 or less, clinical tumor stage of 2A or less, and ...
Clinical disease stage in PCOS was determined from the clinical data available at diagnosis and was based on biopsy results, prostate-specific antigen levels and digital rectal examination. It was recorded as tumour size, nodal involvement and presence or absence of metastases; these were combined ...
12 Specialist visits were defined for each patient as visits to a urologist, radiation oncologist, or medical oncologist from the time of diagnostic biopsy to either treatment date or 9 months after diagnosis, whichever occurred first. Linkage between Medicare claims and the AMA Masterfile was ...
Gleason score on needle core biopsy was categorized into 2 to 6, 7, 8, and 9 to 10. PSA at diagnosis was expressed in nanograms per milliliter (to convert to micrograms per liter, multiply by 1), and grouped into 0.0 to 6.0 ng/mL, 6.1 to 8.0 ng/mL, 8.1 to 15.0 ng/mL, and ...